-
Mashup Score: 4
Over the last 20 years, standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have progressed from cytokines and vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs) to immune checkpoint inhibition (ICI)–based treatment. The availability of these , however, can vary worldwide.
Source: www.medpagetoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14The View on GU | with Lalani and Wallis - 3 month(s) ago
Listen to The View on GU | with Lalani and Wallis on Spotify. There is currently a lack of organic multi-disciplinary discussion on what is truly impactful to the field of genitourinary (GU) cancers. The View on GU with Lalani and Wallis is a podcast that will integrate key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians. Importantly, Lalani and Wallis will also discuss the impact of governmental approvals and funding considerations on the GU oncology treatment landscape and provide practical considerations on the management of patients on new-to-market therapies.
Source: open.spotify.comCategories: General Medicine News, Hem/OncsTweet-
Discussions from #GU24 @WallisCJD - 1L mCRPC combos require clear testing pathways upfront, & when is NHA ➡️ NHA best - peri-op care in #bladder ca & #RCC - IO inj at home? Spotify🎧https://t.co/lvwGksdvYw Apple 🎧 https://t.co/CaYPPP15JI Youtube 💻 https://t.co/6lKjI2VhGs
-
-
Mashup Score: 1
Adjuvant and neoadjuvant therapies that reduce the risk of renal cell carcinoma (RCC) recurrence remain an area of unmet need. Advances have been made in metastatic RCC recently by leveraging PD-1/…
Source: Taylor & FrancisCategories: Hem/Oncs, Latest HeadlinesTweet-
On the eve of #GU23 (excited to see 🌍 friends!), a nice review by @Pooya_Dibajnia of the current adjuvant #RCC space: - roads that led here - ongoing multi-D opportunities 🔓 https://t.co/B5XhjKony0 @luisamcardenas @tandfonline @machealthsci @HamHealthSci @McMasterU @OncoAlert https://t.co/J7pWF0ENKY
-
-
Mashup Score: 0
Atezolizumab as adjuvant therapy after resection for patients with renal cell carcinoma with increased risk of recurrence showed no evidence of improved clinical outcomes versus placebo. These study results do not support adjuvant atezolizumab for treatment of renal cell carcinoma.
Source: The LancetCategories: Hem/Oncs, Latest HeadlinesTweet-
Out in @TheLancet https://t.co/y2AYVwW8vx See @montypal excellent thread 🧵 https://t.co/odpZXkwVKN
-
-
Mashup Score: 24
Introduction Immuno-oncology therapies, including immune checkpoint inhibitors (ICIs), have transformed cancer care and have brought into question whether classic oncology efficacy assessments adequately describe the distinctive responses observed with these agents. With more ICI-based therapies being approved across multiple tumor types, it is essential to define unique clinical hallmarks of…
Categories: Latest Headlines, Oncologists1Tweet-
RT @jitcancer: New #JITC review: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies https://t.co/dM76Holub6…
-
-
Mashup Score: 1
Introduction Immuno-oncology therapies, including immune checkpoint inhibitors (ICIs), have transformed cancer care and have brought into question whether classic oncology efficacy assessments adequately describe the distinctive responses observed with these agents. With more ICI-based therapies being approved across multiple tumor types, it is essential to define unique clinical hallmarks of…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Open Access: our @jitcancer review on unique clinical hallmarks for ICI-therapies in cancer. Learned much from working this group, led by Olivier Michielin @CHUVLausanne, Caroline Robert @GustaveRoussy, Pam Sharma @MDAndersonNews, & @peters_solange 🙏 👉 https://t.co/F1akiDpkuB https://t.co/YwdC6QjYBR
-
-
Mashup Score: 0
In this podcast, Dr. Nimira Alimohamed and Dr. Aly-Khan Lalani review the recent data from trials in advanced bladder cancer including the 5-year survival update of the KEYNOTE-045 trial presented at ASCO in June 2021. The hosts will discuss the impact of immunotherapy and other novel therapeutic strategies on the management of patients with advanced bladder cancer in Canada.
Categories: Latest Headlines, Oncologists1Tweet-
RT @CanUrolAssoc: 🆕🎙️#Listenandlearn We are happy to offer you some summer listening! New @ CUA #UrologyPodcast: https://t.co/jSRYjll9y4 Av…
-
-
Mashup Score: 28Health Canada authorizes Janssen COVID-19 vaccine - Canada.ca - 3 year(s) ago
Today, Health Canada authorized the COVID-19 vaccine manufactured by Janssen Inc. Health Canada received an application from Janssen Inc. for authorization of its COVID-19 vaccine on November 30, 2020. After a thorough, independent review of the evidence, the Department has determined that the vaccine meets Canada’s stringent safety, efficacy and quality requirements.
Source: www.canada.caCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @GovCanHealth: Health Canada authorizes Janssen #COVID19 vaccine: https://t.co/nPqhsCIzQr
-
-
Mashup Score: 2Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma - 3 year(s) ago
This cohort study examines treatment with immune checkpoint inhibitors for patients with metastatic renal cell carcinoma.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Brief thread of our work in @JAMAOnc: @DrChoueiri @DrDanielHeng @ZiadBakouny @FDonskov @ShaanDudani https://t.co/K3fEoAMszc First: #RCC "paradox" of improved OS with ⬆️ BMI in VEGF-TT era was shown by @AlbigesL et al. ➡️ FASN pathway implicated https://t.co/AzOHkDIcaa https://t.co/XhF1oaRrkY
-
-
Mashup Score: 1Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study - PubMed - 3 year(s) ago
Ruth L Kirschstein Research Service Award, American Society of Clinical Oncology Young Investigator Award, MSK’s Ludwig Center, Weiss Family Kidney Research Fund, Novartis, The Sidney Kimmel Center for Prostate and Urologic Cancers, and the National Institutes of Health (National Cancer Institute) C …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Quest remains to elucidate biological underpinnings ▶️ FWIW: In subset of >300 patients with available NGS, we found genomic alteration frequencies, TMB were similar by BMI groups ▶️ See work by @arihakimi et al. on peritumoral tissue inflammation https://t.co/LM6BQ2CIve
-
Chatted w/ @medpagetoday on our @JCOGO_ASCO study on the evolution of systemic #RCC therapy in Canada, highlighting the levers in public health care systems https://t.co/mhEQDRIGf3 Yeoman effort by @luisamcardenas w/ @UroOncMD @DrDanielHeng @nbasappaCCI @SiTanguay & many! 👏 🙏 https://t.co/vcYJtKrKIi https://t.co/3dttBJAVuD